Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-29T03:07:04.788Z Has data issue: false hasContentIssue false
  • English
  • Français

YPSP01-02 - Effectiveness, Quality Of Life And Changes In Burden Of Disease In Children And Adolescents With Adhd Transitioning To Oros Mph

Published online by Cambridge University Press:  17 April 2020

C. Wolff ,
F. Mattejat ,
S. Dichter  and
B. Schaeuble
C. Wolff
Affiliation:
Child and Adolescent Medicine, Private Practice, Hagen, Neuss, Germany
F. Mattejat
Affiliation:
Dept. of Child and Adolescent Psychiatry, University of Marburg, Marburg, Neuss, Germany
S. Dichter
Affiliation:
Janssen Cilag GmbH, Neuss, Germany
B. Schaeuble
Affiliation:
EMEA Medical Affairs, Janssen Cilag GmbH, Neuss, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective

To explore effectiveness, quality of life outcomes, burden of disease in children and adolescents with ADHD transitioning from ER MPH or Atomoxetine onto PR OROS MPH.

Methods

Twelve week open label study including 224 patients (aged 6-18) with ADHD (ICD-10) transitioning from ER MPH (N=180), Atomoxetine (N=42) or both (N=2) onto flexibly dosed PR OROS MPH. Starting dose was based on clinical judgement. Assessments included Children's Global Assessment Scale, IOWA Conners' parent rating scale, quality of life (ILC), and open question related to late afternoon or evening activities.

Results

224 patients (85.3% boys, median age 11 yrs) were documented. 81% completed the study. Median starting and final dose of PR OROS MPH was 36 mg/d. Mean C-GAS improved from 58 ± 15 (previous ER MPH group) and 54 ± 11 (previous ATX group) to 71±16 (12±15; p< 0,01) and 64±18 (9±16; p< 0.001), respectively.

Playing with other children, doing household chores, behavior towards visitors and doing homework were improved after switching from ATX to OROS MPH (all p < 0.05), but not for going to bed (p = 0.57). All items improved in the previous ER MPH group (p < 0.0001). Symptoms measured on IOWA Connor's rating scale as well as burden of disease (ILC) improved in children, adolescents as well as their care givers (p < 0.005).

Conclusion

Transition from ER MPH and ATX onto PR OROS MPH was associated with improved functionality, social interaction and decreased burden of disease in children and adolescents with ADHD.

Type
YP Scholar poster
Information
European Psychiatry , Volume 25 , Issue S1: 18th European Congress of Psychiatry. February 27, March 2, 2010 - Munich, Germany , 2010 , 25-E1682
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.